| Literature DB >> 36043400 |
Qingyu Chen1, Alexis Allot1, Robert Leaman1, Rezarta Islamaj1, Jingcheng Du2, Li Fang3, Kai Wang3,4, Shuo Xu5, Yuefu Zhang5, Parsa Bagherzadeh6, Sabine Bergler6, Aakash Bhatnagar7, Nidhir Bhavsar7, Yung-Chun Chang8, Sheng-Jie Lin8, Wentai Tang9, Hongtong Zhang9, Ilija Tavchioski10,11, Senja Pollak11, Shubo Tian12, Jinfeng Zhang12, Yulia Otmakhova13, Antonio Jimeno Yepes14, Hang Dong15, Honghan Wu16, Richard Dufour17, Yanis Labrak18, Niladri Chatterjee19, Kushagri Tandon19, Fréjus A A Laleye20, Loïc Rakotoson20, Emmanuele Chersoni21, Jinghang Gu21, Annemarie Friedrich22, Subhash Chandra Pujari23,22, Mariia Chizhikova24, Naveen Sivadasan25, Saipradeep Vg25, Zhiyong Lu1.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has been severely impacting global society since December 2019. The related findings such as vaccine and drug development have been reported in biomedical literature-at a rate of about 10 000 articles on COVID-19 per month. Such rapid growth significantly challenges manual curation and interpretation. For instance, LitCovid is a literature database of COVID-19-related articles in PubMed, which has accumulated more than 200 000 articles with millions of accesses each month by users worldwide. One primary curation task is to assign up to eight topics (e.g. Diagnosis and Treatment) to the articles in LitCovid. The annotated topics have been widely used for navigating the COVID literature, rapidly locating articles of interest and other downstream studies. However, annotating the topics has been the bottleneck of manual curation. Despite the continuing advances in biomedical text-mining methods, few have been dedicated to topic annotations in COVID-19 literature. To close the gap, we organized the BioCreative LitCovid track to call for a community effort to tackle automated topic annotation for COVID-19 literature. The BioCreative LitCovid dataset-consisting of over 30 000 articles with manually reviewed topics-was created for training and testing. It is one of the largest multi-label classification datasets in biomedical scientific literature. Nineteen teams worldwide participated and made 80 submissions in total. Most teams used hybrid systems based on transformers. The highest performing submissions achieved 0.8875, 0.9181 and 0.9394 for macro-F1-score, micro-F1-score and instance-based F1-score, respectively. Notably, these scores are substantially higher (e.g. 12%, higher for macro F1-score) than the corresponding scores of the state-of-art multi-label classification method. The level of participation and results demonstrate a successful track and help close the gap between dataset curation and method development. The dataset is publicly available via https://ftp.ncbi.nlm.nih.gov/pub/lu/LitCovid/biocreative/ for benchmarking and further development. Database URL https://ftp.ncbi.nlm.nih.gov/pub/lu/LitCovid/biocreative/. Published by Oxford University Press 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.Entities:
Mesh:
Year: 2022 PMID: 36043400 PMCID: PMC9428574 DOI: 10.1093/database/baac069
Source DB: PubMed Journal: Database (Oxford) ISSN: 1758-0463 Impact factor: 4.462